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Umbilical cord blood is a useful stem cell source for patients
without matched donors, but the low cell dose in individual cord
blood units has limited success in adults. We treated 43 patients
using a reduced intensity conditioning regimen of ﬂudarabine 30
mg/m2/day Days –8 through –3 (total dose 180 mg/m2), melpha-
lan 100 mg/m2 Day –2 and rabbit antithymocyte globulin 1.5
mg/kg Days –7,5,3,1 (total dose 6 mg/kg). Cord blood units
were a 4/6 or higher HLA A, B, DR allele match with the patient
and each other and achieved a minimum precryopreservation cell
dose of 3.7 10 (7) NC/kg. Twenty-one patients received GVHD
prophylaxis with cyclosporine and mycophenolate mofetil and 22
patients received tacrolimus and sirolimus. Median age was 49
years and majority of patients had acute leukemia or relapsed
lymphoma. The median days to neutrophil and platelet engraft-
ment were 20 and 41 days respectively for the cyclosporine/MMF
group and 21 days and 47 days for the tacrolimus/sirolimus pa-
tients. The incidence of acute GVHD Grades II-IV and chronic
GVHD in the cyclosporine/MMF group was 40% and 34% re-
spectively and 14% and 20% respectively for the tacrolimus/siroli-
mus patients. Transplant related mortality was 14% in both
groups. Overall survival and disease free survival were 57% and
57% at 2 years respectively for the cyclosporine/MMF patients and
73% and 51% at one year for the tacrolimus/sirolimus patients. In
a multivariate analysis, age greater than 50 was the only signiﬁcant
predictor of poorer survival. Chimerism studies revealed that one
cord unit predominates in 73% of patients. Predictors of the
predominant unit include ﬁrst infusion and higher CD34 and
nucleated cell counts. Double cord blood transplantation can be
performed safely with this reduced intensity regimen; the graft vs
leukemia effect is preserved despite a low rate of graft versus host
disease.
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INFECTION AND IMMUNE RECONSTITUTION AFTER HSCT: CHAL-
LENGES AND OPPORTUNITIES
Bruce R. Blazar University of Minnesota, MN
Post-BMT immune deﬁciency causes signiﬁcant morbidity and
mortality especially in allotransplant recipients. Despite hemato-
poietic engraftment and recovery of marrow function, recipients
have prolonged defects in generation of functional T and B lym-
phocytes. The clinical signiﬁcance has become evident in studies
utilizing high doses of pre-BMT cytotoxic therapy, donor hema-
topoietic stem cell (HSC) sources depleted of mature T lympho-
cytes, HLA-mismatched donors, and the use of potent lymphocyte
depleting antibodies. Most recipients of T-cell replete matched
sibling or unrelated donor HSC grafts experience late post-BMT
infections, the majority of which are viral and fungal, consistent
with T and B cell lymphopenia and dysfunction. A major cause of
post-BMT immune deﬁciency is the loss of thymopoietic capacity,
and impaired T cell recovery as a result of factors such as age,
radiation or graft-versus-host-disease (GVHD). Normal thymo-
poiesis depends on the interaction of the thymic stroma-derived
receptors and ligands. Damage to thymic epithelial cells by pre-
BMT conditioning impairs the ability of the thymus to generate
mature T lymphocytes after BMT. Approaches to lessen the injury
or hasten the repair of or replace thymic epithelial cell or stromal
elements or their products represent a promising strategy to speed
peripheral T cell reconstitution and function. Common lymphoid
progenitor cells (CLPs) migrate to the thymus where they receive
cues for development into mature thymocytes through a series of
deﬁned maturation steps that are time-dependent. Approaches to
increase the total number or homing of CLPs to the thymus or
alternatively to begin the thymic maturation process ex vivo may
shorten the time to peripheral T cell recovery. Such approaches
may result in extrathymic T cell maturation as well. B cell deﬁ-
ciency post-BMT can be prolonged, especially with injuries such as
GVHD and conditioning regimens that affect stromal cells and
secondary lymphoid organ architecture.
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MULTIVARIATE ANALYSIS OF PATIENT AND GRAFT SPECIFIC FACTORS
AMONG 330 RECIPIENTS OF UNRELATED CORD BLOOD TRANSPLANT
(UCBT) TO PREDICT RISK OF DEATH FROM OPPORTUNISTIC INFEC-
TIONS (OI) IN THE FIRST 6 MONTHS AFTER UCBT
Paul Szabolcs, MD Duke University, Durham, NC
Over the past 5 years we have studied the reconstitution of
immunity in the immediate post-UCBT period in 200 pediatric
recipients of single unit UCB at Duke University to identify sur-
rogate laboratory markers for those at risk for OI.
Several graft and patient-speciﬁc variables were also identiﬁed
as signiﬁcant factors when the laboratory measurements of den-
dritic and T cell reconstitution were analyzed. The overwhelm-
ing majority of OI related death occurs in the ﬁrst 6 months
after UCBT. To determine the impact of patient and graft-
speciﬁc factors on 6-month post-UCBT OI-related mortality
we reviewed all consecutive pediatric UCB recipients trans-
planted at Duke between June 1999 and Oct. 2005. Three
hundred thirty (330) pediatric recipients of single UCB grafts
were identiﬁed. Those receiving a second transplant for primary
graft failure were not analyzed. Two hundred twenty (220) of
the 330 patients (67%) were alive at 6 months. Of the 110
children who died by 6 months, 64 patients (58%) were identi-
ﬁed with OI (viral, fungal, protozoal infections) implicated as a
cause of death. The 46 patients who died prior to 6 months and
for whom OI was not implicated as a cause of death were
omitted from the study dataset, resulting in 284 patients. Of
these 284 patients, 220 patients (77%) were alive at 6 months
and 64 (23%) died at or before 6 months with cause of death
related to OI. Twenty two (22) patients died related to adeno-
virus infection and twelve (12) due to CMV infection, rendering
these two viruses the cause in 50% of all OI related deaths. A
logistic regression model was used to investigate the impact of
ten demographic and clinical characteristics on the risk of death
due to OI by 6 months post UCBT. These potential predictors
were gender, race, age at UCBT, CMV serology, HLA mis-
matches, malignancy, total body irradiation, total graft cell
dose/kg, CD34 graft cell dose/kg and CD3 graft cell dose/
kg, In univariate analyses, gender (p0.28), race (0.12) and TBI
(p0.80) did not predict 6-month death due to OI. Malignancy
(p0.07) was marginally associated with a greater probability of
6-month death due to OI. Malignancy without TBI was also
associated with a marginally higher probability of 6-month
death due to OI (p0.04). A signiﬁcantly greater probability of
6-month OI-related death was associated with CMV positive
serology (p0.0001), greater HLA mismatch (p0.006), and older
age (p0.0009). Higher total graft cell dose (p0.001), CD34
cell dose (p0.014) and CD3 cell dose (0.014) were associated
with lower probability of death due to OI at 6 months. Since
treatment with TBI was closely related to age two multivariable
models were ﬁt. Model 1 included; CMV (p0.0004), HLA
mismatch (p0.042) and Age (p0.03). Model 2 included;
CMV (p0.0001), HLA mismatch (p0.005) and malignancy
without TBI (p0.04). Since total graft cell dose, CD34 cell
dose and CD3 cell dose were also highly correlated, each of
these variables was introduced into models 1) and 2) separately.
Total graft cell dose was the strongest predictor when cell dose
variables were added to Models 1 (p0.0097) and 2 (p0.004).
CD34 cell dose contributed less signiﬁcantly to both models
(p0.02 for both models) while CD3 cell dose was signiﬁcant
in Model 2 only (p0.05). In Model 1 total graft cell dose and
CD34 cell dose replaced age because cell dose/kg inversely
correlates with age. The percent concordance among these
models ranged from 71-75%. Thus, in the pediatric cohort
6-month death due to OI can be predicted by the following risk
factors: older age, positive CMV serology, 1 HLA mismatch,
malignancy without TBI, and lower graft cell dose (total,
CD34 and CD3). In contrast, gender, race and TBI alone do
not predict 6-month death due to OI.
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